Managing Editor, Europe
Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.
Latest From Kevin Grogan
BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.
Following a positive opinion from the CHMP, the Spanish company is hoping to launch its challenger to Dupixent in the EU before the end of the year.
First Wave is licensing Sanofi’s 5-HT4 receptor partial agonist capeserod and is having to pay a mere $500,000 in upfront fees for the privilege.
MSD and Astellas have joined Lilly, Takeda and AstraZeneca in making major investments in Ireland this year.
These are interesting times for Mironid, a Glasgow-based biotech developing small molecule therapeutics for the treatment of autosomal dominant polycystic kidney disease, a life-threatening hereditary condition.
AstraZeneca's Fasenra has demonstrated non-inferiority compared with GSK's fellow interleukin-5 inhibitor Nucala for eosinophilic granulomatosis with polyangiitis and the company hopes its more convenient single monthly subcutaneous injection will win market share if approved for the rare, immune-mediated inflammatory disease.